Harnessing real-world data to inform treatment decisions in multiple sclerosis

Consensus is lacking regarding the initiation and sequencing of disease-modifying therapies (DMTs) for management of multiple sclerosis (MS), resulting in variable use in clinical practice. As novel DMTs with different efficacy and safety profiles emerge based on clinical trials, it is increasingly important to compare the effectiveness and safety of DMTs in clinical practice. Comparing individual therapies in a pairwise fashion in a robust randomized clinical trial (RCT) is costly, rarely occurs, and may not generalize well to the clinical setting, given that clinical trial populations often exclude individuals with comorbidities and of extreme ages.1

Source link

Related posts

Position effect, cryptic complexity, and direct gene disruption as disease mechanisms in de novo apparently balanced translocation cases.


clinical neurology; +305 new citations


FDA Goes Ahead With Approval of Sufentanil Despite Controversy


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy